Vir Biotechnology, Inc. (VIR)
9.96
-0.51
(-4.87%)
USD |
NASDAQ |
Oct 16, 16:00
9.80
-0.16
(-1.61%)
After-Hours: 20:00
Vir Biotechnology Research and Development Expense (Annual) : 432.80M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 432.80M |
| December 31, 2024 | 463.19M |
| December 31, 2023 | 550.92M |
| December 31, 2022 | 467.86M |
| December 31, 2021 | 442.20M |
| Date | Value |
|---|---|
| December 31, 2020 | 296.14M |
| December 31, 2019 | 139.48M |
| December 31, 2018 | 97.47M |
| December 31, 2017 | 62.08M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Moderna, Inc. | 2.917B |
| Vaxcyte, Inc. | 794.31M |
| Caribou Biosciences, Inc. | 109.44M |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| Oncolytics Biotech, Inc. | 13.31M |